The 18 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 162.50, with a high estimate of 210.00 and a low estimate of 45.00. The median estimate represents a +30.18% increase from the last price of 124.83.
The current consensus among 21 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.47
Reporting Date May 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.